"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00338481|
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : July 27, 2011
|Condition or disease||Intervention/treatment||Phase|
|Dyspnea Lung Neoplasms||Drug: Morphine p.o. Drug: Morphine s.c.||Phase 4|
Breathlessness or dyspnea in terminal cancer patients with lung cancer is common and opioids such as morphine is the mainstay of symptomatic treatment. Subcutaneous administration of morphine provides fast symptomatic relief, but it has been the impression in our institution that "red morphine drops" applied orally may have equal or better efficacy and faster onset time.
Comparison: Patients with lung cancer or lung metastases with moderate to severe dyspnea at rest are treated with either orally applied "red morphine drops" or an equivalent amount of morphine applied subcutaneously.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
|Active Comparator: 1||
Drug: Morphine p.o.
Morphine p.o. in "red morphine drops" calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c.
|Active Comparator: 2||
Drug: Morphine s.c.
False "red morphine drops" without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg
- Dyspnea on a VAS scale [ Time Frame: 1 hour ]
- Respiratory rate, pulse rate, oxygen saturation [ Time Frame: 1 hour ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00338481
|Sankt Lukas Hospice|
|Copenhagen, Hellerup, Denmark, 2900|
|Principal Investigator:||Torben Krantz, Physician||Sankt Lukas Hospice|